RU2351594C2 - Способ получения дулоксетина и используемые при этом промежуточные соединения - Google Patents

Способ получения дулоксетина и используемые при этом промежуточные соединения Download PDF

Info

Publication number
RU2351594C2
RU2351594C2 RU2005122662/04A RU2005122662A RU2351594C2 RU 2351594 C2 RU2351594 C2 RU 2351594C2 RU 2005122662/04 A RU2005122662/04 A RU 2005122662/04A RU 2005122662 A RU2005122662 A RU 2005122662A RU 2351594 C2 RU2351594 C2 RU 2351594C2
Authority
RU
Russia
Prior art keywords
duloxetine
acid
salt
addition salt
acid addition
Prior art date
Application number
RU2005122662/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005122662A (ru
Inventor
Дхармарадж Рамачандра РАО (IN)
Дхармарадж Рамачандра РАО
Раджендра Нараянрао КАНКАН (IN)
Раджендра Нараянрао КАНКАН
Original Assignee
Сипла Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2351594(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сипла Лтд filed Critical Сипла Лтд
Publication of RU2005122662A publication Critical patent/RU2005122662A/ru
Application granted granted Critical
Publication of RU2351594C2 publication Critical patent/RU2351594C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
RU2005122662/04A 2002-12-19 2003-12-10 Способ получения дулоксетина и используемые при этом промежуточные соединения RU2351594C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0229583.0 2002-12-19
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein

Publications (2)

Publication Number Publication Date
RU2005122662A RU2005122662A (ru) 2006-01-20
RU2351594C2 true RU2351594C2 (ru) 2009-04-10

Family

ID=9949985

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005122662/04A RU2351594C2 (ru) 2002-12-19 2003-12-10 Способ получения дулоксетина и используемые при этом промежуточные соединения

Country Status (24)

Country Link
US (1) US7645890B2 (https=)
EP (2) EP1587801B1 (https=)
JP (1) JP5259048B2 (https=)
KR (1) KR100926723B1 (https=)
CN (2) CN101125848B (https=)
AT (1) ATE353081T1 (https=)
AU (2) AU2003292396B2 (https=)
BR (1) BR0316902A (https=)
CA (1) CA2510750A1 (https=)
DE (1) DE60311599T2 (https=)
ES (1) ES2279971T3 (https=)
GB (1) GB0229583D0 (https=)
HR (1) HRP20050657A2 (https=)
IL (1) IL169232A (https=)
IS (1) IS7915A (https=)
MA (1) MA27706A1 (https=)
MX (1) MXPA05006659A (https=)
NZ (2) NZ569874A (https=)
PL (1) PL377380A1 (https=)
PT (1) PT1587801E (https=)
RU (1) RU2351594C2 (https=)
TN (1) TNSN05167A1 (https=)
WO (1) WO2004056795A1 (https=)
ZA (1) ZA200505656B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550605B2 (en) * 2004-08-05 2009-06-23 Sun Pharmaceutical Industries Ltd. Process for preparation of an anitdepressant compound
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP1776049A2 (en) * 2005-01-27 2007-04-25 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
WO2006096809A1 (en) 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
TW200639162A (en) * 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
WO2007038253A2 (en) * 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate and methods of preparation thereof
EP1863782A1 (en) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
EP1971593A2 (en) * 2005-12-12 2008-09-24 Medichem, S.A. Improved synthesis and preparations of duloxetine salts
CZ299270B6 (cs) * 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP1976844A4 (en) * 2006-01-06 2010-11-03 Msn Lab Ltd IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
CA2640212A1 (en) * 2006-02-13 2007-08-23 Teva Pharmaceutical Industries Ltd. A process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate
HU228458B1 (en) * 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
SI1857451T1 (sl) 2006-05-05 2010-11-30 Fidia Farmaceutici Postopek priprave intermediata ki je uporaben zaasimetrično sintezo duloksetina
US20080027128A1 (en) * 2006-05-23 2008-01-31 Santiago Ini Duloxetine HCL polymorphs
EP2044049A2 (en) 2006-07-03 2009-04-08 Ranbaxy Laboratories Limited Process for the preparation of enantiomerically pure salts of n-methyl- 3 -( 1-naph-thaleneoxy)- 3 - (-2-thienyl) propanamine
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
HU227730B1 (en) 2006-12-22 2012-01-30 Richter Gedeon Nyrt Process for the preparation of duloxetine and for their the intermediates
CN101657438A (zh) 2006-12-22 2010-02-24 斯索恩有限公司 制备度洛西汀和相关化合物的方法
US8269023B2 (en) 2007-03-05 2012-09-18 Lupin Ltd. Process for preparation of duloxetine hydrochloride
WO2009019719A2 (en) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Process for the preparation of 3-aryloxy-3-arylpropanamines
WO2009130708A2 (en) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Preparation of duloxetine and its salts
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
EP2329013B1 (en) 2008-08-27 2015-10-28 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2011033366A2 (en) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Process for the preparation of duloxetine hydrochloride and its precursors
CN103360365A (zh) * 2012-04-06 2013-10-23 李晓红 一种抗抑郁症药物原料药盐酸度洛西汀的制备新工艺
CN104230882B (zh) * 2014-08-29 2017-03-08 宁波美诺华药业股份有限公司 一种度洛西汀盐酸盐杂质的制备方法
CN104829587B (zh) * 2015-05-08 2017-07-21 上海万巷制药有限公司 盐酸度洛西汀的制备
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457559A2 (en) * 1990-05-17 1991-11-21 Eli Lilly And Company Chiral synthesis of 1-aryl-3-aminopropan-1-ols
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
WO2000061540A1 (en) * 1999-04-09 2000-10-19 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH578532A5 (https=) * 1971-08-03 1976-08-13 Cassella Farbwerke Mainkur Ag
PL233786A1 (https=) 1980-11-14 1982-05-24 Lilly Co Eli
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
JPS62286959A (ja) * 1986-06-05 1987-12-12 Seitetsu Kagaku Co Ltd 光学活性シアノカルニチン塩の製造方法
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
JPH09176157A (ja) * 1992-12-09 1997-07-08 Takeda Chem Ind Ltd 光学活性アミノクマラン誘導体
US6458955B1 (en) 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
US6162949A (en) 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders
HUP0101901A3 (en) * 1998-05-22 2002-06-28 Lilly Co Eli Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
CA2350531A1 (en) * 1998-11-13 2000-05-25 Smriti Iyengar Method for treating pain
WO2001044166A1 (en) * 1999-12-17 2001-06-21 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
WO2003062219A1 (en) 2002-01-24 2003-07-31 Eli Lilly And Company Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457559A2 (en) * 1990-05-17 1991-11-21 Eli Lilly And Company Chiral synthesis of 1-aryl-3-aminopropan-1-ols
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
RU2127269C1 (ru) * 1993-10-12 1999-03-10 Эли Лилли Энд Компани Способ получения (s)-(+)-n,n-диметил-3-(1-нафталинилокси)-3-(2-тиенил)пропанамина и фосфорнокислая соль (s)-(+)-n,n-диметил-3-(1-нафталинилокси)-3-(2- тиенил)пропанамина
WO2000061540A1 (en) * 1999-04-09 2000-10-19 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof

Also Published As

Publication number Publication date
EP1690861B1 (en) 2012-09-12
NZ569874A (en) 2009-11-27
DE60311599T2 (de) 2007-10-25
ES2279971T3 (es) 2007-09-01
AU2003292396B2 (en) 2010-05-20
CN1747947A (zh) 2006-03-15
AU2010200142A1 (en) 2010-02-04
PT1587801E (pt) 2007-04-30
NZ540881A (en) 2008-09-26
ATE353081T1 (de) 2007-02-15
EP1690861A2 (en) 2006-08-16
EP1587801A1 (en) 2005-10-26
IL169232A (en) 2010-02-17
WO2004056795A8 (en) 2005-08-11
CA2510750A1 (en) 2004-07-08
KR20050089839A (ko) 2005-09-08
EP1587801B1 (en) 2007-01-31
CN100579975C (zh) 2010-01-13
MXPA05006659A (es) 2006-02-22
ZA200505656B (en) 2006-04-26
HRP20050657A2 (en) 2005-10-31
JP2006514030A (ja) 2006-04-27
JP5259048B2 (ja) 2013-08-07
AU2010200142B2 (en) 2012-04-12
EP1690861A3 (en) 2006-09-06
RU2005122662A (ru) 2006-01-20
DE60311599D1 (de) 2007-03-22
TNSN05167A1 (en) 2007-05-14
MA27706A1 (fr) 2006-01-02
PL377380A1 (pl) 2006-02-06
US7645890B2 (en) 2010-01-12
GB0229583D0 (en) 2003-01-22
AU2003292396A1 (en) 2004-07-14
BR0316902A (pt) 2005-10-25
US20060205956A1 (en) 2006-09-14
KR100926723B1 (ko) 2009-11-16
IS7915A (is) 2005-06-24
CN101125848B (zh) 2012-09-12
WO2004056795A1 (en) 2004-07-08
CN101125848A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
RU2351594C2 (ru) Способ получения дулоксетина и используемые при этом промежуточные соединения
JP2002541235A (ja) ３−アリールオキシ−３−アリールプロピルアミン及びその中間体の製造方法
JPH10500119A (ja) アザ二環式誘導体の製法
JP2001519385A (ja) キラル化合物の製造方法
EP1758879B1 (en) Method of manufacturing (s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
US7550605B2 (en) Process for preparation of an anitdepressant compound
EP2132192B1 (en) Novel process for preparation of duloxetine hydrochloride
EP1857451B1 (en) A process for the preparation of an intermediate useful for the asymmetric synthesis of (+)duloxetine
JP2000504684A (ja) 第４級キラル中心のラセミ化
CZ296345B6 (cs) Zpusob výroby hydrochloridu (R)-N-methyl-3-(2-methylfenoxy)-3-fenylpropylaminu (atomoxetinu)
PL217679B1 (pl) Sposób wytwarzania duloksetyny

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20131211